Pharma firm Aurobindo said it has received approval from the US regulator for three of its drugs used in the treatment of attention deficit, hepatitis C and hyperactivity.
The company gets the US Food and Drug Administration (USFDA) tentative approval for Atomoxetine Hydrochloride Capsules and final approvals for Ribavirin Tablets and Ribavirin Capsules, Aurobindo said in a filing to the Bombay Stock Exchange.
Atomoxetine Hydrochloride Capsules are in the strengths of 10mg, 18mg, 25mg, 40mg, 60mg, 80mg and 100mg and Ribavirin Tablets in the 200mg strength and Ribavirin Capsules in 200mg strength, the filing added.
Aurobindo now has a total of 106 Abbreviated New Drug Application (ANDA) approvals (76 final approvals and 29 tentative approvals from USFDA, the filing added.
Aurobindo Pharma settled at Rs 677.05 on Friday, down 2.49 per cent from previous close.